Literature DB >> 23845694

Distinct deleterious effects of cyclosporine and tacrolimus and combined tacrolimus-sirolimus on endothelial cells: protective effect of defibrotide.

Alba Carmona1, Maribel Díaz-Ricart, Marta Palomo, Patricia Molina, Marc Pino, Montserrat Rovira, Ginés Escolar, Enric Carreras.   

Abstract

Endothelial dysfunction seems to be a key factor in the development of several complications observed early after hematopoietic stem cell transplantation (HSCT). The conditioning regimen and many other factors associated with the procedure are responsible for this endothelial damage. The effects of immunosuppressive agents on endothelial function have not been explored in detail. We evaluated the effects of 3 drugs commonly used in HSCT: 2 calcineurin inhibitors, cyclosporine A (CSA) and tacrolimus (TAC), and an inhibitor of mTOR, sirolimus (SIR). We also evaluated the effect of the combination of TAC and SIR (TAC+SIR), which is used increasingly in clinical practice. Microvascular endothelial cells (HMEC-1) were exposed to these drugs to evaluate changes in (1) intercellular adhesion molecule (ICAM)-1 expression on the cell surface, assessed by immunofluorescence labeling and expressed as the mean gray value (MGV); (2) reactivity of the extracellular matrix (ECM) toward platelets, upon exposure of the ECM to circulating blood; and (3) whole-blood clot formation, assessed by thromboelastometry. Studies were conducted in the absence and presence of defibrotide (DF) to assess its possible protective effect. The exposure of HMEC-1 to CSA and TAC+SIR significantly increased the expression of ICAM-1 (157.5 ± 11.6 and 153.4 ± 9.5 MGV, respectively, versus 105.7 ± 6.5 MGV in controls [both P < .05]). TAC applied alone increased ICAM-1 slightly (120.3 ± 8.2 MGV), and SIR had no effect (108.9 ± 7.4 MGV). ECM reactivity increased significantly only in response to CSA (surface covered by platelets of 41.2% ± 5.4% versus 30.1% ± 2.0%, P < .05). DF attenuated all these changes. No significant changes in the viscoelastic properties of clot formation were observed in any condition with blood samples incubated in vitro. In conclusion, CSA and TAC+SIR had a proinflammatory effect, but only CSA exhibited an additional prothrombotic effect. Interestingly, DF exerted clear protective anti-inflammatory and antithrombotic effects on the endothelium.
Copyright © 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cyclosporine; Endothelial damage; Immunosuppressive agents; Sirolimus; Tacrolimus; mTOR

Mesh:

Substances:

Year:  2013        PMID: 23845694     DOI: 10.1016/j.bbmt.2013.07.001

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  23 in total

1.  What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance.

Authors:  Marta Palomo; Enrique Mir; Montse Rovira; Ginés Escolar; Enric Carreras; Maribel Diaz-Ricart
Journal:  Blood       Date:  2016-01-11       Impact factor: 22.113

2.  Biomarkers for Diagnosis and Prognosis of Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation.

Authors:  Ayman Akil; Qing Zhang; Christen L Mumaw; Nisha Raiker; Jeffrey Yu; Nieves Velez de Mendizabal; Laura S Haneline; Kent A Robertson; Jodi Skiles; Maribel Diaz-Ricart; Enric Carreras; Jamie Renbarger; Samir Hanash; Robert R Bies; Sophie Paczesny
Journal:  Biol Blood Marrow Transplant       Date:  2015-07-11       Impact factor: 5.742

Review 3.  The use of defibrotide in blood and marrow transplantation.

Authors:  Paul G Richardson; Enric Carreras; Massimo Iacobelli; Bijan Nejadnik
Journal:  Blood Adv       Date:  2018-06-26

4.  The induction strategies administered in the treatment of multiple myeloma exhibit a deleterious effect on the endothelium.

Authors:  Julia Martinez-Sanchez; Marta Palomo; Sergi Torramade-Moix; Ana Belen Moreno-Castaño; Montserrat Rovira; Gonzalo Gutiérrez-García; Francesc Fernández-Avilés; Gines Escolar; Olaf Penack; Laura Rosiñol; Enric Carreras; Maribel Diaz-Ricart
Journal:  Bone Marrow Transplant       Date:  2020-05-13       Impact factor: 5.483

Review 5.  New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy.

Authors:  Sonata Jodele; Christopher E Dandoy; Kasiani C Myers; Javier El-Bietar; Adam Nelson; Gregory Wallace; Benjamin L Laskin
Journal:  Transfus Apher Sci       Date:  2016-04-25       Impact factor: 1.764

6.  Endothelial damage is aggravated in acute GvHD and could predict its development.

Authors:  E Mir; M Palomo; M Rovira; A Pereira; G Escolar; O Penack; E Holler; E Carreras; M Diaz-Ricart
Journal:  Bone Marrow Transplant       Date:  2017-06-26       Impact factor: 5.483

Review 7.  Angiogenic factors and inflammation in steroid-refractory acute graft-vs-host disease.

Authors:  Shernan G Holtan; Mukta Arora
Journal:  Transl Res       Date:  2015-06-09       Impact factor: 7.012

Review 8.  Defibrotide: a review of its use in severe hepatic veno-occlusive disease following haematopoietic stem cell transplantation.

Authors:  Gillian M Keating
Journal:  Clin Drug Investig       Date:  2014-12       Impact factor: 2.859

Review 9.  A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury.

Authors:  Sonata Jodele; Benjamin L Laskin; Christopher E Dandoy; Kasiani C Myers; Javier El-Bietar; Stella M Davies; Jens Goebel; Bradley P Dixon
Journal:  Blood Rev       Date:  2014-11-28       Impact factor: 8.250

Review 10.  Transplant-associated thrombotic microangiopathy: opening Pandora's box.

Authors:  E Gavriilaki; I Sakellari; A Anagnostopoulos; R A Brodsky
Journal:  Bone Marrow Transplant       Date:  2017-03-13       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.